Published in Drug Saf on February 01, 2013
Usage patterns of 'over-the-counter' vs. prescription-strength nonsteroidal anti-inflammatory drugs in France. Br J Clin Pharmacol (2014) 0.86
Liver transplant associated with paracetamol overdose: results from the seven-country SALT study. Br J Clin Pharmacol (2015) 0.80
Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs Aging (2016) 0.79
Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-wide Association Study. Gastroenterology (2016) 0.77
Etiologies and outcomes of acute liver failure in a spanish community. Int J Hepatol (2013) 0.76
Immunogenomics reveal molecular circuits of diclofenac induced liver injury in mice. Oncotarget (2016) 0.75
Usage patterns of paracetamol in France. Br J Clin Pharmacol (2016) 0.75
The past, present and perhaps future of pharmacovigilance: homage to Folke Sjoqvist. Eur J Clin Pharmacol (2013) 0.75
Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology (2005) 10.66
Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol (1993) 7.63
Early indicators of prognosis in fulminant hepatic failure. Gastroenterology (1989) 7.43
Drug-induced hepatotoxicity. N Engl J Med (2003) 7.11
Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol (1990) 5.66
Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology (2009) 3.88
Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol (1993) 2.89
Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology (2010) 2.26
Staggered overdose pattern and delay to hospital presentation are associated with adverse outcomes following paracetamol-induced hepatotoxicity. Br J Clin Pharmacol (2012) 1.91
Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology (1986) 1.59
The therapeutic applications of and risks associated with acetaminophen use: a review and update. J Am Dent Assoc (2011) 1.56
Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology (2010) 1.51
Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ (2003) 1.42
Acute liver failure. Postgrad Med J (2005) 1.42
Paracetamol: past, present, and future. Am J Ther (2000) 1.31
Therapeutic misadventure with paracetamol: fact or fiction? Am J Ther (2000) 1.27
Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol (2010) 1.22
Paracetamol, alcohol and the liver. Br J Clin Pharmacol (2000) 1.19
Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis (2007) 1.14
Liver injury caused by drugs: an update. Swiss Med Wkly (2010) 1.08
Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study. Pharmacoepidemiol Drug Saf (2007) 0.94
Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol (2010) 0.93
Paracetamol in therapeutic dosages and acute liver injury: causality assessment in a prospective case series. BMC Gastroenterol (2011) 0.93
Administrative complexities for a European observational study despite directives harmonising requirements. Pharmacoepidemiol Drug Saf (2012) 0.93
FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable? Inflammopharmacology (2010) 0.91
Idiosyncratic drug-induced liver injury: a clinical update. Curr Gastroenterol Rep (2011) 0.89
Fatal liver failure in a patient on acetaminophen treated with sunitinib malate and levothyroxine. Ann Pharmacother (2009) 0.88
Concordance between prescriber- and patient-reported previous medical history and NSAID indication in the CADEUS cohort. Pharmacoepidemiol Drug Saf (2010) 0.87
Molecular mechanism of diclofenac hepatotoxicity: Association of cell injury with oxidative metabolism and decrease in ATP levels. Toxicol In Vitro (1995) 0.87
Pirprofen-induced fulminant hepatitis. Gastroenterology (1985) 0.85
The CADEUS study: methods and logistics. Pharmacoepidemiol Drug Saf (2007) 0.84
Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. Pharmacoepidemiol Drug Saf (2010) 0.84
Severe idiosyncratic acute hepatic injury caused by paracetamol. J Hepatol (1998) 0.82
[Criteria of imputation of acute hepatitis to a drug. Results of consensus meetings]. Gastroenterol Clin Biol (1987) 0.81
When patients report diseases that prescribers seem unaware of: discordance between patient and physician reporting of risk-related previous history in NSAID users from the CADEUS study. Clin Pharmacol Ther (2010) 0.80
The case-population study design: an analysis of its application in pharmacovigilance. Drug Saf (2011) 0.77
Comparison of patient questionnaires, medical records, and plasma assays in assessing exposure to benzodiazepines in elderly subjects. Clin Pharmacol Ther (2001) 0.76
Early liver transplantation for severe alcoholic hepatitis. N Engl J Med (2011) 8.50
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology (2007) 4.44
Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol (2013) 4.24
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet (2009) 4.11
Choice of time-scale in Cox's model analysis of epidemiologic cohort data: a simulation study. Stat Med (2004) 3.93
How to improve care in outpatients with cirrhosis and ascites: a new model of care coordination by consultant hepatologists. J Hepatol (2013) 3.75
Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology (2008) 3.67
Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. Int J Epidemiol (2006) 3.36
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol (2005) 3.27
Liver fibrosis: non-invasive assessment with MR elastography. NMR Biomed (2006) 3.21
Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index. Radiology (2007) 3.12
Clinical and imaging evidence of zolpidem effect in hypoxic encephalopathy. Ann Neurol (2007) 3.02
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood (2006) 3.00
Source and characterization of hepatic macrophages in acetaminophen-induced acute liver failure in humans. Hepatology (2012) 2.81
New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance. Mov Disord (2004) 2.76
The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol (2006) 2.74
Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol (2005) 2.62
Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf (2010) 2.57
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet (2011) 2.50
Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol (2002) 2.41
Guidelines for submitting adverse event reports for publication. Drug Saf (2007) 2.38
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2010) 2.32
Relation between liver progenitor cell expansion and extracellular matrix deposition in a CDE-induced murine model of chronic liver injury. Hepatology (2009) 2.23
Spironolactone and risk of upper gastrointestinal events: population based case-control study. BMJ (2006) 2.18
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology (2011) 2.16
Immediate listing for liver transplantation versus standard care for Child-Pugh stage B alcoholic cirrhosis: a randomized trial. Ann Intern Med (2009) 2.16
Antipsychotic use and myocardial infarction in older patients with treated dementia. Arch Intern Med (2012) 2.16
Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf (2013) 2.15
Detection of minimal hepatic encephalopathy: normalization and optimization of the Psychometric Hepatic Encephalopathy Score. A neuropsychological and quantified EEG study. J Hepatol (2008) 2.14
UK legislation on analgesic packs: before and after study of long term effect on poisonings. BMJ (2004) 2.11
Inflammation-based scores do not predict post-transplant recurrence of hepatocellular carcinoma in patients within Milan criteria. Liver Transpl (2014) 2.11
Candida as a risk factor for mortality in peritonitis. Crit Care Med (2006) 2.07
The effects of coffee and napping on nighttime highway driving: a randomized trial. Ann Intern Med (2006) 2.04
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol (2010) 2.02
Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology (2012) 2.01
Old versus new antiepileptic drugs: the SANAD study. Lancet (2007) 1.99
Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose-containing intravenous immunoglobulins: a case-control study. Pharmacoepidemiol Drug Saf (2011) 1.98
Idiopathic cholangiopathy in a biliary cast syndrome necessitating liver transplantation following head trauma. Eur J Gastroenterol Hepatol (2003) 1.98
Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol (2010) 1.97
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology (2012) 1.97
Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf (2009) 1.96
Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA (2013) 1.94
Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol (2012) 1.94
Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ (2011) 1.88
Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl (2006) 1.86
Kupffer cell activation is a causal factor for hepatic insulin resistance. Am J Physiol Gastrointest Liver Physiol (2009) 1.85
Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf (2003) 1.81
A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology (2003) 1.73
Cytomegalovirus-induced gammadelta T cells associate with reduced cancer risk after kidney transplantation. J Am Soc Nephrol (2009) 1.72
Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol (2010) 1.70
Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection : an observational multicenter study. Liver Transpl (2007) 1.64
Renal function, efficacy and safety postconversion from twice- to once-daily tacrolimus in stable liver recipients: an open-label multicenter study. Transpl Int (2012) 1.62
Fatigue, sleep restriction and driving performance. Accid Anal Prev (2005) 1.60
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol (2006) 1.58
From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis (2011) 1.58
Intake of energy drinks in association with alcoholic beverages in a cohort of students of the School of Medicine of the University of Messina. Alcohol Clin Exp Res (2007) 1.57
Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases. Surgery (2010) 1.56
Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut (2010) 1.55
Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. Radiology (2003) 1.55
Differences between clinical trials and postmarketing use. Br J Clin Pharmacol (2004) 1.54
12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl (2006) 1.53
Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients. Liver Transpl (2005) 1.52
The impact of organ dysfunction in cirrhosis: survival at a cost? J Hepatol (2012) 1.52
Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice: a study in a French emergency department. Drug Saf (2002) 1.51
Hui and Walter's latent-class reference-free approach may be more useful in assessing agreement than diagnostic performance. J Clin Epidemiol (2005) 1.51
Character and temporal evolution of apoptosis in acetaminophen-induced acute liver failure*. Crit Care Med (2013) 1.51
Inhibition of Cell Growth and Cellular Protein, DNA and RNA Synthesis in Human Hepatoma (HepG2) Cells by Ethanol Extract of Abnormal Savda Munziq of Traditional Uighur Medicine. Evid Based Complement Alternat Med (2011) 1.51
Evidence of rebalanced coagulation in acute liver injury and acute liver failure as measured by thrombin generation. Liver Int (2013) 1.50
Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf (2012) 1.50
Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients: a controlled clinical trial. Liver Transpl (2002) 1.50
Characteristics of minimal hepatic encephalopathy. Metab Brain Dis (2004) 1.47
Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. J Hepatol (2011) 1.47
A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology (2004) 1.47
Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol (2006) 1.47
Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database. Pharmacoepidemiol Drug Saf (2008) 1.47
Alcohol relapse after liver transplantation for alcoholic liver disease: does it matter? J Hepatol (2003) 1.47
Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology (2006) 1.46
Design and validation of an automated method to detect known adverse drug reactions in MEDLINE: a contribution from the EU-ADR project. J Am Med Inform Assoc (2012) 1.46
Cognitive impairment and electroencephalographic alterations before and after liver transplantation: what is reversible? Liver Transpl (2014) 1.46
Herbal medicine hepatotoxicity: a new step with development of specific biomarkers. J Hepatol (2010) 1.45
Rates of spontaneous reporting of adverse drug reactions in France. JAMA (2002) 1.45
Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study. Eur J Heart Fail (2006) 1.45
A qualitative exploration of the major challenges facing pharmacovigilance in Saudi Arabia. Saudi Med J (2015) 1.45
Interdisciplinary treatment of ruptured cerebral aneurysms in elderly patients. J Neurosurg (2010) 1.44
Limitations of compensated Jaffe creatinine assays in cirrhotic patients. Clin Biochem (2011) 1.43
Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France. Am J Hematol (2015) 1.42
Spinal anesthesia failure after local anesthetic injection into cerebrospinal fluid: a multicenter prospective analysis of its incidence and related risk factors in 1214 patients. Reg Anesth Pain Med (2011) 1.41
The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine (2012) 1.41
Fluvastatin reduces cardiac mortality in patients with coronary heart disease. Cardiovasc Drugs Ther (2004) 1.40
Benzodiazepines and injurious falls in community dwelling elders. Drugs Aging (2008) 1.39
Alpha2 -adrenoceptor function in arterial hypertension associated with obesity in dogs fed a high-fat diet. J Hypertens (2002) 1.39
Patterns and correlates of benzodiazepine use in the French general population. Eur J Clin Pharmacol (2004) 1.39